Center-Authored Papers

Filters: Author is Roth, Joshua A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Carlson JJ, Thariani R, Roth J, Gralow J, Henry LN, Esmail L, Deverka P, Ramsey SD, Baker L, Veenstra DL.  2013.  Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics.. Medical decision making : an international journal of the Society for Medical Decision Making. 33(4):463-71. Abstract
Carlson JJ, Roth JA.  2013.  The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.. Breast cancer research and treatment. 141(1):13-22. Abstract
Carter-Harris L, Brandzel S, Wernli KJ, Roth JA, Buist DSM.  2017.  A qualitative study exploring why individuals opt out of lung cancer screening.. Family practice. Abstract
E
Esmail LC, Roth J, Rangarao S, Carlson JJ, Thariani R, Ramsey SD, Veenstra DL, Deverka P.  2013.  Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research.. Genetics in medicine : official journal of the American College of Medical Genetics. 15(2):115-122. Abstract
F
Forrester SH, Hepp Z, Roth JA, Wirtz HS, Devine EB.  2014.  Cost-Effectiveness of a Computerized Provider Order Entry System in Improving Medication Safety Ambulatory Care. Value in Health. 17(4):340-349.
H
Hart R, Veenstra DL, Boudreau DM, Roth JA.  2016.  The Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.. The American journal of medicine. Abstract
J
Jones SMW, Gell NM, Roth JA, Scholes D, LaCroix AZ.  2015.  The Relationship of Perceived Risk and Biases in Perceived Risk to Fracture Prevention Behavior in Older Women.. Annals of behavioral medicine : a publication of the Society of Behavioral Medicine. 49(5):696-703. Abstract
R
Roth JA, Bensink ME, O'Donnell PV, Fuchs EJ, Eapen M, Ramsey SD.  2014.  Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer.. Journal of comparative effectiveness research. 3(2):135-44. Abstract
Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R.  2016.  Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.. JAMA oncology. Abstract
Roth JA, Garrison LP, Burke W, Ramsey SD, Carlson R, Veenstra DL.  2011.  Stakeholder perspectives on a risk-benefit framework for genetic testing.. Public health genomics. 14(2):59-67. Abstract
Roth JA, Bradley K, Thummel KE, Veenstra DL, Boudreau D.  2015.  Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.. Pharmacoepidemiology and drug safety. 24(6):619-627. Abstract
Roth JA, Ramsey SD.  2016.  Computed Tomography Screening for Lung Cancer: A High-Value Proposition? JAMA. 315(1):77-8.
Roth JA, Carlson JJ.  2011.  Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.. Clinical lung cancer. 12(6):393-401. Abstract
Roth JA, Etzioni R, Waters TM, Pettinger M, Rossouw JE, Anderson GL, Chlebowski RT, Manson JE, Hlatky M, Johnson KC et al..  2014.  Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial: A Modeling Study.. Annals of internal medicine. 160(9):594-602. Abstract
Roth JA, Sullivan SD, Goulart BHL, Ravelo A, Sanderson JC, Ramsey SD.  2015.  Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare.. Journal of oncology practice / American Society of Clinical Oncology. 11(4):267-72. Abstract
Roth JA, Boudreau D, Fujii MM, Farin FM, Rettie AE, Thummel KE, Veenstra DL.  2014.  Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.. Clinical pharmacology and therapeutics. 95(6):636-43. Abstract
Roth JA, Ramsey SD, Carlson JJ.  2015.  Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.. The oncologist. 20(12):1355-1364. Abstract
Roth JA, Billings P, Ramsey SD, Dumanois R, Carlson JJ.  2014.  Cost-Effectiveness of a 14-Gene Risk Score Assay to Target Adjuvant Chemotherapy in Early Stage Non-Squamous Non-Small Cell Lung Cancer.. The oncologist. 19(5):466-476. Abstract
Roth JA, Cohen JT, Veenstra DL, Chen E, Jhuti GS, Neumann PJ, Sullivan SD.  2015.  Development of A Cost-Effectiveness Analysis Framework for Modeling Treatment of Alzheimer's Disease And Mild Cognitive Impairment.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 18(7):A698-9.
Roth JA, Carlson JJ.  2012.  Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.. Journal of gastrointestinal cancer. 43(2):215-23. Abstract
Roth JA, Goulart BHL, Ravelo A, Kolkey H, Ramsey SD.  2017.  Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.. The oncologist. 22(3):304-310. Abstract
V
Veenstra DL, Roth JA, Garrison LP, Ramsey SD, Burke W.  2010.  A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice.. Genetics in medicine : official journal of the American College of Medical Genetics. 12(11):686-93. Abstract
W
Wang B, Roth JA, Nguyen H, Felber E, Furnback W, Garrison LP.  2015.  The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.. PloS one. 10(4):e0121915. Abstract